← BackMIMEDX GROUP, INC. · Surgical & Medical Instruments & ApparatusMDXG
Moderate riskNext report: In 0 days (est.)
The short versionA profitable company with shrinking sales. Institutions are adding.
Going well
- Profitable
- Sales up 20% last year
- Brings in more cash than it spends
Watch out for
- Sales down 35% in the latest quarter vs a year ago
- Share count growing 9.9% a year
- 1 offering filing in 6 months (may sell new shares)
Money moves
- No insider buying or selling in the last 30 days
- Institutions added 3.5% to their holdings in the quarter ending June 2026 (127 bought, 108 sold)
Facts from SEC filings, not a recommendation.
What the price means
Price as of Oct 26
$3.86-1.3% that day
- Company value
- $563M
- Share price times all shares
- Price vs profit (P/E)
- 96.5x
- You pay about $96 for each $1 of yearly profit
- Price vs sales
- 1.6x
- Company value is 1.6 times a year of sales
- Cash vs value
- 24%
- Cash as a share of company value
- Debt vs value
- 3%
- Debt as a share of company value
From MDXG's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.
The business over time
Last 12 quarters, from SEC filings
Sales, Jun '26$64.4M-35% vs a year earlier
Sep '23Tap a barJun '26
Last 12 months: $355.2M, down 2.4% from the 12 months before. Over 5 years, sales grew about 11% a year.
Business quality
The checklist Warren Buffett-style investors use. Annual numbers for 2025.- PassReturn on equity 15%+Earns a lot on the money owners have in the business.21.6%
- PassDebt under half of equityNot relying on borrowed money.0.07x equity
- PassNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.11.6%
- MissProfitable every yearSteady profits, not one good year.5 of 10 years
- PassFree cash flow positiveBrings in more cash than it spends to run and grow.$74.0M
- MissShare count not growingNot diluting owners. Falling means buybacks.+32.6% in 3 years
- PassGross margin 40%+Pricing power: sells for well above what it costs to make.82.6%
- Revenue
- $418.6M
- +20.0% vs prior year
- 5-year growth
- +11.0%/yr
- revenue, per year
- Total debt
- $18.0M
- 0.07x equity
- Current ratio
- 4.32x
- short-term assets / bills due
From annual reports filed with the SEC. A checklist is a starting point for research, not a verdict.
Latest quarter
Quarter ended Jun 30, 2026- Revenue
- $64.4M
- -34.7% YoY
- EPS
- -$0.10
- vs $0.06
- Op. margin
- -28.7%
- -41.2 pts
- Gross margin
- 69.0%
- -12.1 pts
- Free cash flow
- -$10.0M
- Share count
- -1.0%
- vs a year ago
Insider rating
Last 90 days
No open-market insider buys or sells in the last 90 days.
Weekly insider trendNo trades to chart yet.
Filing buzz
Last 7 days vs normal
0/ 100
- This week
- 0
- Normal week
- 1.2
- vs normal
- 0.0x
SEC filings of any kind. 50 means a normal week.
Institutional ownership
▲Accumulating+3.5%Institutions added 3.5% to their holdings. 127 bought, 108 sold. 7 quarters of net buying in a row.
Shares held by institutions116.6M
Sep '24Jun '26
Share count growthYearly rate, last 3 years
+7.9%Cash runwayAt last year's cash burn
Cash flow positiveDebt to equityLatest balance sheet: debt compared with what owners have
0.1x · $17.2M debtShares outstandingLatest reported
146MWhy moderate risk- Share count growing 7.9% a year
- 1 offering filing in 6 months (may sell new shares)
Next reportIn 0 days (est.)Estimated from the same quarter last year
- Results filedJul 29
- Results filedApr 29
- Results filedFeb 25
- Results filedOct 29, 2025
- Results filedJul 30, 2025
Insider trades
Open-market buys and sells, last 90 days
No open-market buys or sells in 90 days. Grants and option exercises are left out.
"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.